Floatz logo

Tarlatamab

Brain Metastases, Adult

Maastricht University Medical Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

102 Active assets in the Brain Metastases, Adult cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Tarlatamab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neuroendocrine carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →